KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Research & Development: 2016-2024

Historic Research & Development for Aurinia Pharmaceuticals (AUPH) over the last 9 years, with Dec 2024 value amounting to $20.8 million.

  • Aurinia Pharmaceuticals' Research & Development rose 176.83% to $8.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.7 million, marking a year-over-year increase of 29.73%. This contributed to the annual value of $20.8 million for FY2024, which is 58.13% down from last year.
  • Per Aurinia Pharmaceuticals' latest filing, its Research & Development stood at $20.8 million for FY2024, which was down 58.13% from $49.6 million recorded in FY2023.
  • Aurinia Pharmaceuticals' Research & Development's 5-year high stood at $51.1 million during FY2021, with a 5-year trough of $20.8 million in FY2024.
  • Its 3-year average for Research & Development is $38.5 million, with a median of $45.0 million in 2022.
  • In the last 5 years, Aurinia Pharmaceuticals' Research & Development grew by 10.34% in 2023 and then slumped by 58.13% in 2024.
  • Yearly analysis of 5 years shows Aurinia Pharmaceuticals' Research & Development stood at $50.3 million in 2020, then increased by 1.61% to $51.1 million in 2021, then dropped by 12.03% to $45.0 million in 2022, then grew by 10.34% to $49.6 million in 2023, then tumbled by 58.13% to $20.8 million in 2024.